In this article, we estimate national health care resource use and medical costs in 2007 associated with prediabetes (PD), defined as either fasting plasma glucose between 100 and 125 or oral glucose tolerance test between 140 and 200.
A n estimated 57 million people in the United States have prediabetes (PD), which is characterized by elevated blood glucose levels with either fasting plasma glucose between 100 and 125 or oral glucose tolerance test between 140 and 200. 1 Concerns regarding PD have focused on its role as a precursor to type 2 diabetes, a disease associated with increased risk for cardiovascular disease, renal complications, peripheral vascular disease, neurological complications, endocrine complications, and numerous other chronic health problems. [2] [3] [4] [5] [6] [7] There is growing evidence that even slightly elevated blood glucose levels, as is the case with PD, are associated with higher medical costs 8, 9 and increased risk for certain comorbidities of diabetes-coronary heart disease, [10] [11] [12] [13] [14] retinopathy, 15, 16 hypertension, 17 and even mortality. 18 With nearly 1 in 4 adults (57 million out of 224 million) having PD, even a slight increase in per capita health care use and disease risk has significant implications for the health system. While recent work highlights the significant economic burden associated with diabetes, 19, 20 few studies have investigated the economic burden of PD. 8, 9 We use recent medical claims data to estimate per capita excess health care use associated with PD, and combine this information with national estimates of health care use and medical costs to calculate national expenditures associated with PD. Such cost information is paramount to understanding the business case for interventions directed to improve prevention, screening, and treatment associated with PD.
Research Design and Methods
This study uses a Cost of Diabetes Model, originally developed to quantify the national cost of diagnosed diabetes, that contains estimates of national health care use and costs for comorbidities of diabetes. The data sources and methods used to develop this model, the national health care use and 1 The Lewin Group, Falls Church, Virginia. Ingenix=i3research, Nanterre, France. Funding for this study was provided by the Novo Nordisk, Inc. National Changing Diabetes Program. 10.1089=pop.2009.12302 cost estimates in the model, and the etiological fractions used to determine the proportion of national costs attributed to diagnosed diabetes are described elsewhere. 19 Following is a description of the data and methods used to adapt this model to quantify the national medical costs associated with PD. 
POPULATION HEALTH MANAGEMENT
Volume 12, Number 3, 2009 ª Mary Ann Liebert, Inc. DOI:
Data

Analysis of health resource care use patterns
We used Poisson regression to analyze patterns of health care resource use associated with neurological symptoms, peripheral vascular disease, cardiovascular disease, renal complications, endocrine complications, ophthalmic complications, and other complications of diabetes. The diagnosis 158 ZHANG ET AL.
codes used to define these complication categories are described elsewhere. 19 In addition, we analyze an ''other'' category that includes care provided for all reasons not included in the 8 categories previously specified but excluding care associated with injuries and pregnancy.
For each comorbidity group we estimate separate regressions for ambulatory visits, emergency visits, and inpatient days. Poisson regression allows us to isolate the relationship between PD status and health care service use, controlling for other determinants of health care use. The estimating equation is:
where PD, and Gr1 through Gr3 are dichotomous variables: PD ¼ 1 if identified with PD in identification year and 0 otherwise; Gr1 through Gr3 correspond to being in comparison groups 1 through 3 (1 in comparison group, 0 otherwise). Comparison group 4 has been omitted as the reference group. The row vector control i represents an array of dichotomous variables indicating age group, sex, health insurance type (either commercial or public), Census region, year, and the presence of select diabetes complications and costly health conditions during the PD identification year (ie, peripheral vascular disease, cardiovascular disease, hypertension, endocrine complications, ophthalmic complications, pregnancy, neoplasm, HIV=AIDS, and organ transplantation).
In addition to regressions that included all 3.5 million adults, to test the sensitivity of our findings we estimated separate regressions for males, non-pregnant females, and pregnant females.
Estimating attributable cost
The data and methods used to calculate national estimates of health care use (eg, ambulatory visits, medications), by diagnosis category, are described elsewhere. 19 The approach combines per capita estimates of physician office visits (from the NAMCS) and outpatient visits (from the NHAMCS) with Census Bureau population estimates for 2007 by age and sex. We use the primary diagnosis code to place the visit into one of the 8 aforementioned diagnosis categories.
We calculate etiological fractions to determine the portion of national visits associated with PD. 23 Health care use attributed to PD is calculated as the proportion of visits incurred (I) by people with PD minus the visits that are likely to have occurred even in the absence of PD. To derive these estimates from national totals, we must also determine the proportion of visits incurred by people with diagnosed diabetes mellitus (DDM) and undiagnosed (UDM) diabetes mellitus. The DDM population is defined as individuals with an FPG that exceeds 125. UDM is defined as unknowingly having elevated glucose levels that meet the definition of diabetes.
The Poisson regressions, described later, produce rate ratios (RR) that reflect the ratio of annual ambulatory visits (visits) for people with PD compared with people with assumed normal glucose levels (NGL). Estimates of prevalence and rate ratios for DDM come from work by Dall et al 19 ; rate ratios for UDM come from other work by the authors. 24 Combining rate ratios and prevalence rates (P), we calculate etiological fractions (e) for PD by age group, sex, and complication group:
Multiplying total visits and the etiological fractions produces estimates of excess visits associated with PD by demographic and complication group. Estimates of the national average cost (including pharmaceuticals) associated with each visit, by complication group, are estimated using the Medical Expenditure Panel Survey and are described elsewhere. 19 
Results
When multiplied by population estimates for 2007 from the Census Bureau, PD prevalence rates from the NHANES suggest there are 57 million adults living with PD. Prevalence rates vary by demographic, ranging from approximately 9% for women age 20-34 to over 42% for males age 65 and older.
The RDM data contain 10,502 people with a glucose test result in 2004 in the normal or PD range. This represents only 0.3% of the analyzed population. The comparison group (ie, those with no test or no test results) therefore contains a significant number of people with PD (which could bias toward 0 the estimates of differences between the PD and comparison groups). Pregnant women are overrepresented in the population receiving a glucose test in 2004; they constitute 6% of the population who test positive for PD and 14.7% of the population who test negative for PD. Women with a glucose level indicating gestational diabetes are excluded from the analysis ( Table 1) .
The Poisson regression analysis suggests that PD is associated with increased ambulatory visits, but we found no consistent evidence of an association between PD and increased risk of emergency visits and inpatient days. Consequently, we assume PD is not associated with medical services that might stem from emergency visits and hospitalizations (eg, hospice care, nursing home care, home care).
Regression coefficients in the form of rate ratios are reported in Table 2 . A coefficient greater than 1 implies an increased rate of health care use associated with that characteristic. The increase in per capita ambulatory visits from PD for the 7 complication categories is slight, and for some complication groups the increase is not statistically significant (Table 2 ). With the exception of hypertension and endocrine-related care, we observed a dose-response relationship by comparison group, where people diagnosed with diabetes have the greatest adjusted rates for ambulatory visits in the follow-up year, followed by individuals who had at least 1 glucose test, and individuals who had no test. People who had a glucose test in the year preceding analysis of medical claims, regardless of the results, have higher rates of health care use than the population who did not have a glucose test, even after controlling for baseline health status, demographics, and other factors.
We use the adjusted rate ratio between confirmed PD and the reference group (ie, individuals without either diabetes diagnosis or glucose test) to calculate the incremental ambulatory visits associated with PD. Patients with confirmed PD have approximately 34% more ambulatory visits per year compared to the reference population-ranging from 9% more visits for cardiovascular disease and peripheral vascular disease to 92% more visits for hypertension.
The additional visits associated with PD translate into approximately 1 additional physician office visit per year, 1=10 th of an additional hospital outpatient visit per year, and 2.7 additional prescriptions per year-for a total additional cost of $443 per case of PD (Table 3 ). The majority of PDassociated costs per year are for general medical conditions that are not identified comorbidities of diabetes ($355), followed by hypertension ($57), endocrine and metabolic complications ($11=person year), and renal complications ($9=person year) ( Table 3 ).
Extrapolated to the national level by patient demographics, the national cost of PD would exceed $25 billion, with about $21 billion associated with general medical conditions not directly linked to diabetes. For diagnosed diabetes, approximately one third of the cost of ambulatory care associated with diabetes is attributed to excess visits for general medical conditions. 19 Close to half of the total cost is in the form of medications prescribed during ambulatory visits.
Discussion
Our findings differs from those of Nichols et al who report that predicted impaired glucose tolerance is associated with Logged rate ratios are reported. *significant at 5%; **significant at 1% based on robust standard error. Separate regressions for split samples for males, nonpregnant females, and pregnant females found consistent coefficient estimates with the overall model. PDM, prediabetes mellitus; FPG, fasting plasma glucose; OGGT, oral glucose tolerance test. a significant increase in hospital inpatient days but only a modest increase in ambulatory visits. 9 The increase in hospital days observed by Nichols et al, however, disappears after controlling for hypertensive status.
The lack of statistical significance for some complication groups, despite the consistent pattern of higher rates of visits for people with PD, is not surprising for several reasons, including: (1) PD is hypothesized to be associated with the early stages of diabetes-related complications, therefore the magnitude of PD's impact on health care use is anticipated to be modest; (2) the comparison group is contaminated in that it contains people with PD for whom there is no glucose test result in the baseline year; and (3) visit rates for some complication groups are relatively low, so modest differences in health care use patterns are undetectable due to insufficient sample size.
For one complication group-ophthalmic complicationsthe visit rates for people with PD are lower than the rate for those with confirmed normal glucose levels. This unexpected finding may reflect an artifact of referral patterns by ophthalmologists for patients with ophthalmic problems. PD is associated with higher visit rates for general medical conditions even controlling for the presence of major chronic conditions at baseline.
Our estimate is likely conservative for several reasons. The comparison group includes people with PD who did not have a glucose test in 2004 (and who thus, by default, are placed in the comparison group).
These cost estimates understate the true cost of PD to society, as higher use of health care services and prevalence of chronic conditions such as cardiovascular disease are associated with increases in missed work days and lower productivity. [25] [26] [27] [28] Additionally, health problems associated with PD may result in intangible costs such as reduced quality of life.
In addition to the data limitations above that make the PD cost estimates conservative, study limitations include the following:
The elderly, the uninsured, and the publicly insured are underrepresented in the medical claims analysis-although the regression analysis does control for insurance type, age group, and other health and demographic factors correlated with the elderly and publicly insured populations. We did not control for body weight status in the multivariate regression analyses. This presents challenges to isolate the impact of glucose intolerance on health outcomes independent of the changes in health outcomes via pathways other than PD. The regression analysis does control for hypertension status at baseline (which is highly correlated with body mass index). 29 These limitations and gaps in the literature suggest areas for additional research.
We compare use of medical services by people with PD to people with normal glucose levels. Research using a more continuous measure, such as actual glucose test results, could better determine whether there is a dose-response relationship between level of glucose impairment and use of health care services.
Although this study found no association between PD and increased use of emergency or hospital inpatient services, additional research with a larger sample is needed to verify this finding.
Small sample size limited the calculation of visit rate ratios by PD status across beneficiary characteristics (age in particular). Future research might explore the interaction between PD and other beneficiary characteristics including demographics and the presence of other complications.
Conclusions
The findings suggest that PD is associated with statistically higher rates of ambulatory visits for hypertension, endocrine and metabolic complications, renal complications, and general medical conditions. PD is associated with a slight increase in visit rates for neurological symptoms, peripheral vascular disease, and cardiovascular disease, but the increase is not statistically significant. There is no indication that PD is associated with an increase in emergency visits and=or inpatient days. Extrapolating these patterns to the 57 million adults with PD in 2007 suggests that national medical costs of PD could exceed $25 billion, or approximately $443 per adult with PD.
Research suggests that PD is associated with an increased risk of developing diabetes. [2] [3] [4] [5] [6] [7] Whereas adults in the United States with normal glucose levels have a 0.7% average annual risk of developing type 2 diabetes, 2 this risk rises to between 10% and 15% for those with PD. [3] [4] [5] As many as 83% of persons with impaired glucose tolerance will eventually develop diabetes, barring a lifestyle intervention such as weight loss, but this lifetime risk falls to 65% among persons who lose weight and engage in moderate physical activity. 6, 7 Our findings strengthen the business case for lifestyle interventions targeted at preventing diabetes by adding additional economic benefits that can potentially be achieved by preventing or delaying PD cases.
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